Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008725 | 0.95 | ALDH1A1 (0.69) | MEN1KMT2AMAPTALDH1A1NCOA3 | |
| SCHEMBL18539159 | 0.91 | CA9 (0.57) | MEN1KMT2AMAPTALDH1A1NCOA3 | |
| SCHEMBL12008478 | 0.90 | MEN1 (0.81) | MEN1KMT2AMAPTNPC1POLB | |
| SCHEMBL12008477 | 0.84 | NPC1 (0.79) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL12008479 | 0.84 | PKM (0.60) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL12008788 | 0.83 | MAPT (0.87) | MEN1KMT2AMAPTALDH1A1NCOA3 | |
| SCHEMBL12008746 | 0.83 | ALDH1A1 (0.62) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL12008758 | 0.79 | MAPT (1.00) | MEN1KMT2AMAPTALDH1A1NCOA3 | |
| SCHEMBL12008723 | 0.78 | MAPT (0.66) | MEN1KMT2AMAPTALDH1A1NCOA3 | |
| SCHEMBL19736098 | 0.76 | MAPT (0.81) | MEN1KMT2AMAPTALDH1A1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MEN1 3747/4885KMT2A 4503/4885MAPT 2143/4885 |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | CTNNB1, CTNNA1, CTNNBL1 | MEN1 4655/4885KMT2A 4591/4885MAPT 1929/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MEN1 4655/4885KMT2A 4591/4885MAPT 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.